A prospective cross‐sectional study of anxiety and depression in patients with psoriasis in Singapore

Tee, Shang‐Ian; Lim, Ziying Vanessa; Theng, Colin; Chan, Keen Loong; Giam, Yoke Chin

doi:10.1111/jdv.13615

“…Many clinical characteristics of psoriasis patients are reported to be correlated with psychological disorders, including depression, anxiety, and others [1, 4, 11, 14]. Partially in line with previous studies, our study demonstrated that female gender, long disease duration, and high PASI score were positively associated with depression symptoms, and female gender, large psoriasis-affected BSA, and high PASI score were positively associated with anxiety symptoms in psoriasis patients.…”

Section: Discussionsupporting

confidence: 81%

“…Therefore, the disease duration was longer in depressed patients compared with non-depressed patients in our study. Finally, as the indexes for evaluating psoriasis severity, the higher scores of psoriasis-affected BSA and PASI represent more severe skin conditions of psoriasis, which is positively correlated with psychiatric conditions and may exacerbate depression and anxiety in psoriasis patients [1, 4]. Additionally, more severe disease is associated with poorer quality of life, which could also exacerbate mental disorder in psoriasis patients [19].…”

Section: Discussionmentioning

confidence: 99%

“…Symptoms regularly reported by psoriasis patients include pain, itching, bleeding, or scaling, and patients may be awkward about the visible disfiguration of their skin, which has a substantial negative influence on psychological well-being [3, 4]. As the most common psychological problems, depression and anxiety are relatively frequent in psoriasis patients, with depression prevalence ranging from 9 to 62% and anxiety prevalence ranging from 11 to 43% [4, 5]. Many conventional therapies for psoriasis, such as vitamin D derivatives, corticosteroids, methotrexate, ciclosporin, acitretin, and phototherapy, have been applied to patients for many years.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Depression Symptoms Predict Worse Clinical Response to Etanercept Treatment in Psoriasis Patients

Jin

¹

,

Zhang

²

,

Duan

³

2018

View full text Add to dashboard Cite

Background/Aims: This study aimed to investigate the predicting values of depression and anxiety symptoms for clinical response to etanercept treatment in psoriasis patients. Methods: A total of 85 psoriasis patients who received 6 months of etanercept treatment were consecutively enrolled in this prospective cohort study. The Psoriasis Area and Severity Index (PASI) score was evaluated at month 0 (M0), M1, M3, and M6, and the corresponding PASI 75/90 response at each visit was assessed. Also, anxiety and depression symptoms were assessed by the Hospital Anxiety and Depression Scale (HADS) at M0, M1, M3, and M6. Results: Depression symptoms were observed to correlate with female gender (p = 0.004), longer disease duration (p = 0.018), and higher PASI score (p < 0.001), and anxiety symptoms were seen to be associated with female gender (p = 0.017), larger psoriasis-affected body surface area (p = 0.049), and higher PASI score (p = 0.017) in psoriasis patients. After etanercept treatment, HADS-Depression (HADS-D) and HADS-Anxiety (HADS-A) scores were both decreased at M1, M3, and M6 (all p < 0.001) compared with M0. Most importantly, baseline depressed patients presented with a lower PASI 75 response rate at M3 (p = 0.014) and M6 (p = 0.005), and a reduced PASI 90 response rate at M6 (p = 0.045) compared with baseline non-depressed patients. Furthermore, multivariate logistic regression analyses revealed that depression symptoms at baseline were an independent predictive factor for the lower possibility of both PASI 75 response (p = 0.048) and PASI 90 response (p = 0.048) achievements at M6 in psoriasis patients. However, no correlation of baseline anxiety symptoms with PASI 75/90 responses was observed. Conclusion: Depression symptoms at baseline independently predict a worse clinical response to etanercept treatment in psoriasis patients.

show abstract

“…Similarly, there was no statistically significant correlation between age and depressive score in cases of psoriasis with GHQ ≥3. These results were supported by the study conducted by Tee et al 19 where also there was no significant corelation between anxiety and depression scores on HADS and the age of the patients. In the present study, on the correlation between age and QOL score in cases of psoriasis with GHQ ≥3, no significant relationship was found.…”

Section: Discussionsupporting

confidence: 82%

Psychiatric Morbidity and Quality of Life in Patients suffering from Psoriasis in a Tertiary Care Hospital

Kumar¹,

Shrivastava²,

Jaiswal³

et al. 2017

International Journal of Advanced and Integrated Medical Sciences

0

View full text Add to dashboard Cite

Introduction: Psoriasis is an inflammatory skin disease, which may be persistent, disfiguring, and stigmatizing. The disease is frequent, with prevalence estimates ranging from 0.3 to 2.5%. It is characterized by thick, red, scaly lesion that may appear on any part of the body. Psoriasis is associated with significant psychological and psychiatric morbidity, experience of stigmatization, and decreased health-related quality of life (QOL).

show abstract

“…Je nach Studiendesign, untersuchter Population und den zugrunde gelegten diagnostischen Kriterien geben bis zu 62% der Psoriasis-Patienten depressive Symptome an und bis zu 43% der Patienten berichten von Angstgefühlen [2,3]. …”

Section: Transfer In Die Praxis Von Dr Wiebke Sondermann (Essen)unclassified

Depressive Psoriasis-Patienten können ein schlechteres Ansprechen auf Etanercept zeigen

Sondermann¹

2019

Kompass Dermatol

0

View full text Add to dashboard Cite

Background/Aims: This study aimed to investigate the predicting values of depression and anxiety symptoms for clinical response to etanercept treatment in psoriasis patients. Methods: A total of 85 psoriasis patients who received 6 months of etanercept treatment were consecutively enrolled in this prospective cohort study. The Psoriasis Area and Severity Index (PASI) score was evaluated at month 0 (M0), M1, M3, and M6, and the corresponding PASI 75/90 response at each visit was assessed. Also, anxiety and depression symptoms were assessed by the Hospital Anxiety and Depression Scale (HADS) at M0, M1, M3, and M6. Results: Depression symptoms were observed to correlate with female gender (p = 0.004), longer disease duration (p = 0.018), and higher PASI score (p < 0.001), and anxiety symptoms were seen to be associated with female gender (p = 0.017), larger psoriasis-affected body surface area (p = 0.049), and higher PASI score (p = 0.017) in psoriasis patients. After etanercept treatment, HADS-Depression (HADS-D) and HADS-Anxiety (HADS-A) scores were both decreased at M1, M3, and M6 (all p < 0.001) compared with M0. Most importantly, baseline depressed patients presented with a lower PASI 75 response rate at M3 (p = 0.014) and M6 (p = 0.005), and a reduced PASI 90 response rate at M6 (p = 0.045) compared with baseline non-depressed patients. Furthermore, multivariate logistic regression analyses revealed that depression symptoms at baseline were an independent predictive factor for the lower possibility of both PASI 75 response (p = 0.048) and PASI 90 response (p = 0.048) achievements at M6 in psoriasis patients. However, no correlation of baseline anxiety symptoms with PASI 75/90 responses was observed. Conclusion: Depression symptoms at baseline independently predict a worse clinical response to etanercept treatment in psoriasis patients.

show abstract

A prospective cross‐sectional study of anxiety and depression in patients with psoriasis in Singapore

Abstract: This study demonstrates the strong psychiatric morbidity in patients with psoriasis, for which further psychiatric evaluation should be considered.

Cited by 32 publications

References 16 publications

Depression Symptoms Predict Worse Clinical Response to Etanercept Treatment in Psoriasis Patients

Depression Symptoms Predict Worse Clinical Response to Etanercept Treatment in Psoriasis Patients

Psychiatric Morbidity and Quality of Life in Patients suffering from Psoriasis in a Tertiary Care Hospital

Depressive Psoriasis-Patienten können ein schlechteres Ansprechen auf Etanercept zeigen

Contact Info

Product

Resources

About